Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Conducting the trial at the site

Investigational product management

12 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Describe the chain of custody and accountability for investigational product (IP)

  • Explain storage, temperature control and excursions

  • Handle blinding, randomisation and returns or destruction

The investigational product (IP) is the medicine, vaccine, device or placebo being tested or used as a comparator. Careful management ensures participants receive the correct, safe, effective product and that data about dosing can be trusted.

Chain of custody

From the manufacturer to the participant, every handover must be recorded: shipment, receipt, storage, dispensing, return and destruction. Each step has a responsible person, a date and a quantity, so that every unit is accounted for.

Key responsibilities at the site

  • Receipt: check the shipment against the packing list, check condition and temperature data loggers, and record receipt. Quarantine suspect shipments until the sponsor confirms they are usable.
  • Storage: keep in a secure, locked area with access limited to authorised staff and at the labelled temperature (for example 2 to 8 degrees Celsius or room temperature). Use calibrated thermometers or continuous loggers with alarms.
  • Dispensing: according to the protocol and randomisation, by trained delegated staff.
  • Accountability: keep a log of quantities received, dispensed, returned and remaining. Reconcile regularly.
  • Returns and destruction: return unused product to the sponsor, or destroy it as instructed, with documentation.
1ManufacturerLabelled,released2ReceiptCheck, log,quarantine ifneeded3StorageLocked,temperaturecontrolled4DispensingTo the rightparticipant5Return ordestroyReconcile anddocument
The chain of custody. Every step is recorded.

Temperature excursions

An excursion happens when product is stored outside its permitted temperature range. Staff must:

  1. Quarantine the affected product (do not dispense).
  2. Record the duration and temperatures.
  3. Notify the sponsor or CRO at once.
  4. Wait for written instructions on whether the product can still be used.

Randomisation, blinding and unblinding

  • Randomisation allocates participants by chance, usually through a central system or sealed numbered packs, so that the groups are comparable.
  • Allocation concealment hides the next assignment from those enrolling participants. Blinding hides the assignment from participants and staff after allocation.
  • Emergency unblinding is permitted only when knowing the treatment is essential for the participant's safety. The reason is documented, and the sponsor is notified.

Worked example: reconciling accountability

A site received 200 vials of IP. The log shows:

  • Dispensed to participants: 152.
  • Returned unused by participants: 9.
  • Damaged and quarantined: 3.
  • Remaining in the pharmacy count: 40.

Expected remaining = 200 − 152 + 9 − 3 = 54. The physical count is 40, a difference of 14 vials. The pharmacist and CRA investigate: some dispensing entries were recorded as 2 vials instead of 1 for a single dose, and 5 vials were not logged on return. The log is corrected with explanations and signatures, and a deviation is reported. Regular reconciliation caught the problem early.

Accountability protects participants and data

If the number of units does not match, no one can be sure which participants received which dose.

Never use product outside the protocol

IP is for trial participants only. Giving it to others, or using it after an uncorrected excursion, endangers safety and invalidates data.

Check yourself

Draw the chain of custody for a product at your site. At which step is the greatest risk of an unrecorded loss?

Summary

  • Every handover of IP is recorded from manufacturer to destruction.

  • Storage must be secure and within the labelled temperature; excursions are quarantined and reported.

  • Accountability logs are reconciled regularly.

  • Unblinding is only for safety reasons and is documented.

Check your understanding

Question 1
1

After a temperature excursion, staff should:

Question 2
2

A site receives 200 vials, dispenses 152, has 9 returned and 3 damaged. The expected remaining is:

Question 3
3

Emergency unblinding is acceptable when:

Question 4
4

Allocation concealment prevents:

Question 5
5

IP accountability logs record:

Question 6
6

Investigational product should be stored:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Source documents and data integrityAdverse events and serious adverse events